Figure 7
Figure 7. Fibrinolysis markers. Mean (± SE) plasma levels of PA activity (A), PAPc (B), t-PA antigen (C), PAI-1 antigen (D), and PAI-1 activity (E) after LPS administration (4 ng/kg intravenously, T = 0 hours), during one of the following conditions: an LinsuEgluc clamp (□), an LinsuHgluc clamp (○), an HinsuEgluc clamp (■), and an HinsuHgluc clamp (●). *P < .05, **P < .01, and ***P < .001 hyperinsulinemic versus lower insulinemic clamps; †P < .05 hyperglycemic versus euglycemic clamps.

Fibrinolysis markers. Mean (± SE) plasma levels of PA activity (A), PAPc (B), t-PA antigen (C), PAI-1 antigen (D), and PAI-1 activity (E) after LPS administration (4 ng/kg intravenously, T = 0 hours), during one of the following conditions: an LinsuEgluc clamp (□), an LinsuHgluc clamp (○), an HinsuEgluc clamp (■), and an HinsuHgluc clamp (●). *P < .05, **P < .01, and ***P < .001 hyperinsulinemic versus lower insulinemic clamps; †P < .05 hyperglycemic versus euglycemic clamps.

Close Modal

or Create an Account

Close Modal
Close Modal